Actively Recruiting
Phase 12 Evaluation of Dual-Target CAR-NK Cell Therapy for Advanced or Metastatic Non-Small Cell Lung Cancer Targeting MSLN, EGFR, and HER2
Led by Beijing Biotech · Updated on 2026-06-11
60
Participants Needed
1
Research Sites
65 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, feasibility, and preliminary anti-tumor effects of off-the-shelf dual-target CAR-NK cell therapy in adults with advanced or metastatic non-small cell lung cancer NSCLC whose tumors express at least two specific antigens Mesothelin MSLN, EGFR, and HER2ERBB2. This Phase 12 trial aims to identify the best dose and CAR-NK construct for further study, focusing on patients with tumors resistant to standard treatments. Participants receive lymphodepleting chemotherapy with fludarabine and cyclophosphamide over three days before getting an intravenous infusion of dual-target CAR-NK cells matched to their tumors antigen profile. The study has two parts Part A involves dose escalation among three CAR-NK constructs targeting different antigen pairs, while Part B expands treatment at the recommended dose to further evaluate safety and activity. Supportive care, including premedication and management of immune-related side effects, follows institutional guidelines. During the study, participants undergo tumor antigen testing via biopsy or archival tissue. Researchers monitor safety through dose-limiting toxicities within 28 days, and assess anti-tumor responses using imaging every few months. Additional evaluations include CAR-NK cell persistence, immune markers, and correlations with antigen levels. Follow-up lasts up to 12 months to assess disease control, progression, and response duration. Study participation may last up to about two years including follow-up.
CONDITIONS
Brief Title
Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
Research Team
S
shan S Lu, Phd
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here